A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.
Phase of Trial: Phase I
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs NZV 930 (Primary) ; Spartalizumab (Primary) ; Taminadenant (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Cancer; Colon cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 22 Nov 2018 Planned End Date changed from 15 Feb 2022 to 14 Feb 2022.
- 09 Aug 2018 Planned End Date changed from 24 Jan 2022 to 15 Feb 2022.
- 09 Aug 2018 Planned primary completion date changed from 28 Jun 2021 to 24 Jan 2022.